Pioglitazone Ameliorates Lipid Metabolic Disorder in KKAy Mice – Pages 140-146

Pioglitazone Ameliorates Lipid Metabolic Disorder in KKAy Mice – Pages140-146
Sifan Chen1,2, Qing Wei3, Yanshuang Sun1,2, Xincai Xiao1,2,4, Zili Zhang1,2, Liangru Ke5, Niman Zhou5, Zhiming Shan5, Xiang Feng1,2 and Wei Zhu4
1Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Sun Yat-Sen University, Guangzhou, China; 2Faculty of Nutrition, School of Public Health, Sun Yat-Sen University, Guangzhou, Guangdong, People’s Republic of China; 3Faculty of Preventive Medicine, School of Public Health, Sun Yat-Sen University, Guangzhou 510080, PR China; 4Guangzhou Center for Disease Control and Prevention, Guangzhou, Guangdong, People’s Republic of China; 5Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, Guangdong, People’s Republic of China
DOI: http://dx.doi.org/10.6000/1927-5951.2011.01.02.09

Abstract:Pioglitazone (pio) has been used as an effective hypoglycemic drug in medicine, however, the effects and mechanisms of pio on lipid metabolic disorder are still largely unknown. To explore the effects of pio on serum and liver lipid level and antioxidant ability of mice with lipid metabolic disorder, KKAy mice were treated with pio for 12 weeks and their lipid and antioxidant indices were compared to those of KKAy mice without pio treatment. C57BL/6J mice were used as control animals. The results show that pio treatment reduces serum and liver TG, elevates serum HDL-C level, increases serum and liver SOD activity, attenuates serum MDA content, ameliorates liver steatosis, induces liver PPARγ expression and enhances AMPKα phosphorylation level. In conclusion, the results indicate that pio could regulate blood lipid level, reduce liver lipid deposition and enhance antioxidant capacity of mice with lipid metabolic disorder, which is possibly through increasing AMPKα phosphorylation.

Keywords: Pioglitazone, lipid metabolic disorder, AMP-activated protein kinase.